AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors
AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors
AHN癌症研究所将为转移性黑色素瘤提供开创性的治疗方法；由Iovance Biotherapeutics开发的一次性治疗是美国食品药品管理局批准的首种实体瘤T细胞疗法
Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a first-of-its-kind cellular therapy recently approved by the U.S. Food and Drug Administration to treat metastatic melanoma.
阿勒格尼健康网络（AHN）癌症研究所已成为宾夕法尼亚州西部第一个提供同类细胞疗法的医疗保健系统，该疗法最近获得美国食品药品监督管理局的批准，用于治疗转移性黑色素瘤。
Amtagvi provides new hope for adult patients with hard-to-treat melanoma. This includes patients who haven't had success with other medications, have skin cancer that can't be removed through surgery (unresectable), or have skin cancer that has spread throughout the body (metastatic).
Amtagvi为难以治疗的黑色素瘤的成年患者提供了新的希望。这包括未成功使用其他药物的患者、患有无法通过手术切除（不可切除的）皮肤癌或皮肤癌已扩散到全身（转移性）的患者。
The one-time treatment, made by Iovance Biotherapeutics, is the first FDA-approved T-cell therapy...
这种一次性疗法由Iovance ...
登录免费看全文
登录/注册